Peripheral Versus Central Oxytocin Action
THE WIDESPREAD DISTRIBUTION of OT receptors in the brain and the specific behavioral effects of centrally administered OT have clearly established its involvement in a broad range of social behaviors. In this regard, intranasal OT has been shown to increase trusting behavior (36) , positive communication (20) , in-group favoritism (17) and to reduce social stress reactivity (29) . Recently, studies examining human social behaviors have also found on the oxytocin receptor gene (Oxtr) (33) , a single nucleotide polymorphism, rs53576, involving a guanine (G) to adenine (A) substitution located in the third intron. Individuals homozygous for the G allele compared with those with the GA or AA genotypes exhibit greater empathy and maternal sensitivity (63) , confirming that the Oxtr gene is an important candidate in the understanding of human social behaviors (63) .
OT also regulates food intake, predominantly carbohydrate (65) . This action appears to be centrally mediated since overfeeding observed in OT Ϫ/Ϫ and OTR Ϫ/Ϫ mice are reversed after intracerebroventricular OT injection (76, 7) . However, consistent with the OT main function to induce milk ejection reflex in mammals during lactation, the OT-null mice are unable to breastfeed, but this phenotype may be completely rescued after intraperitoneal administration of OT (57), confirming that peripherally supplied oxytocin can rescue the defect. Collectively, this suggests that OT has both central and peripheral actions.
In agreement with the knowledge that calcium is mobilized from the maternal skeleton during late pregnancy and lactation (38) , the assumption that the same hormone regulating these functions might also control skeletal homeostasis led to the discovery of a direct anabolic action of OT on the skeleton (76) . Moreover, the failure of intracerebroventricular OT injections in enhancing bone anabolism indicated that the effect was due to its peripheral action (76) .
Growing relevance of pituitary hormones as endocrine skeletal regulators, large longitudinal studies have correlated their levels to measurements of bone microstructure and bone turnover markers across the menopause transition (70) . In fact, the pituitary-bone axis importance is being widely recognized, indicating that several pituitary hormones regulate skeletal homeostasis, such as growth hormone (GH) (52) , folliclestimulating hormone (FSH) (71) , thyroid-stimulating hormone (TSH) (1) , prolactin (PRL) (66) , oxytocin (76) , and vasopressin (77) . Furthermore, experiments performed in haploinsufficient mice for pituitary hormones or their receptors revealed that the decline of hormone levels seriously affects the skele-ton, while the primary target organ could remain undamaged, indicating that bone has greater sensitivity to the pituitary hormone control (76, 77, 13) . Notably, regarding OT, the skeleton is more sensitive to its action than the breast since haploinsufficient OT ϩ/Ϫ or OTR ϩ/Ϫ mice, while lactating normally, display profound osteopenia.
These recent findings not only update the novel functions of the pituitary gland, but also explain the mechanisms poorly understood of certain forms of osteoporosis. For example, it has hitherto been thought that hyponatremia triggers sodium release from the skeleton by increasing bone resorption and, consequently, inducing bone loss and a high fracture risk (6) . The direct skeletal actions of AVP have never been explored, despite elevated plasma AVP levels were often reported in hyponatremia. Finally, a very recent study has demonstrated that the genetic deletion of Avpr1 or the pharmacologic inhibition of Avpr1 and/or Avpr2, both expressed on osteoclasts and osteoblasts, increased bone mass, stimulating bone formation and inhibiting osteoclast formation and bone resorption (77) . This new finding advances notable perspectives in developing therapies for hyponatremia by using AVPR inhibitors, which could result in bone gain (77) .
The fascinating demonstration that novel circuit of "old pituitary" hormones exist in bone suggest that local production and action of OT and AVP could have evolved to conduct skeletal surveillance.
Anabolic OT Action on the Skeleton
OT-null and OTR-null mice develop low-turnover osteoporosis that worsens with age in both sexes (76) . Histomorphometry and microcomputed tomography revealed a pronounced decrease in vertebral and femoral trabecular volume, already evident in the heterozygous mice, accompanied by a significant reduction in bone formation rate (76) . Both osteoblasts and osteoclasts express OTRs. In vitro osteoblasts from OT Ϫ/Ϫ and OTR Ϫ/Ϫ mice exhibited a decreased number of mineralized nodules, and all of the master genes involved in osteoblast differentiation were negatively regulated. Treatment with recombinant OT administration increased osteoblasts development toward a mineralizing phenotype by inducing upregulation of BMP-2 and ATF-4 pathways (76) . The signaling cascades that mediate OT action on bone cells involved the Ca 2ϩ release from intracellular stores and triggered ERK signaling. This intracellular calcium increase occurred with two different patterns: a single spike, returning immediately back to the baseline in osteoblasts and a slower but long lasting increase in osteoclasts (76) . With regard to the crosstalk between bone cells, OT treatment decreased the expression of osteoprotegerin (OPG) in mature osteoblasts, while increasing RANK-L, thus stimulating osteoclast differentiation. The dual effect of OT on osteoclasts occurred either directly, by activating NF-B and MAPK signaling, or indirectly, through the upregulation of RANK-L. On the other hand, OT inhibited bone resorption by triggering cytosolic Ca 2ϩ release and nitric oxide synthesis (76) . This apparent paradox of increased osteoclastogenesis coupled to temporary decreases in bone resorption can be interpreted in the view of the cyclic activity of OT due to the downregulation of its receptors. The physiological meaning could be the cyclic availability of circulating level of calcium, required for fetal skeleton mineralization and lactation in periods such as the last phases of pregnancy and after parturition. Hence, the last phase of pregnancy and lactation corresponds to maximal fetal and postnatal bone growth periods, respectively, during which the mother loses ϳ120 g of calcium from her skeleton (38) . Analysis of bone density during lactation, revealed a reduction of 3-10% in bone mineral content in lumbar spine, hip, femur, and distal radius at trabecular sites. A reduction at cortical sites, even smaller, was also observed (39, 68) . The bone loss has been quantified as 1-3% per month, thus much higher than the loss of 1-3% per year, which occurs in women with postmenopausal osteoporosis. At the same time, during lactation, low estrogen and elevated PTHrP levels due to hormonal adaptations facilitate this maternal hyperresorption and intergenerational calcium transfer (85) . Pregnant and lactating women thus suffer the most rapid bone loss of their lifetime, up to 10% over 6 mo, mainly at trabecular sites (62) . Nevertheless, after a very short period of acute bone loss, the mother's skeleton is quickly recovered, and if it does not, osteoporosis arising from pregnancy and lactation can occur (69) . Hormonal adaptations orchestrate this important process of intergenerational calcium transfer, during which the fetal skeleton is mineralized at the expense of the mother. This mechanism remained for a long time unknown until the direct role of OT on the skeleton during pregnancy and lactation was revealed. Thus, osteoclast formation was diminished in pregnant mothers with genetic OT deficiency (49) . In view of a plausible role for OT in maternal skeletal remodeling, skeletons of pups at embryonic day 20 (E20) were analyzed. These pups displayed apparently normal skeletons, without bone/cartilage defects. Measurements of trabecular bone at the epiphysis showed no difference in bone volume/total bone volume (BV/TV) However, trabecular number was significantly increased, without any change in trabecular thickness and, consequently, a significant reduction in trabecular spacing (49) . The unchanged BV/TV, even in the face of greater trabecular number, could suggest that each trabeculum is less mineralized, or indeed, that total mineral per unit volume is lower in OT Ϫ/Ϫ pups than in wild-type pups, although mineral per se has not been measured (49) .
Together, these results are consistent with the observation that OT is critical, mainly during pregnancy and lactation, for maintaining a high rate of cell activity in bone, stimulating the proliferation of both forming and resorbing cells, but controlling the amount of bone resorbed.
Estrogen-Mediated OT and OTR Synthesis
Estrogen dependence of OT and its receptor's synthesis (60, 74, 14, 15) have further expanded the significance of OT/ OTR's biological role. Thus, OT is locally produced in several organs (28, 79, 35) and, as in other tissues, estrogen stimulates OT synthesis in bone (14) . In differentiated osteoblasts, 17␤-estradiol stimulates OT production, via a nonclassical, estrogen responsive element (ERE)-independent pathway involving Erk phosphorylation. Indeed, both 17␤-estradiol and the relatively cell-impermeant analog 17␤-estradiol-BSA-conjugate were equally effective in stimulating OT expression within 2 h and Erk1/2 phophorylation within 3 min (14) . Furthermore, the MAPK kinase (MEK1/2) inhibitor PD98059, which blocks ERK phosphorylation, inhibited OT induction in response to 17␤-estradiol (14) . Together, these findings attest a non-genomic, Erk-dependent pathway for the induction of OT by estrogen. Conversely, native 17␤-estradiol, but not the estradiol-BSA-conjugate, enhanced OTR expression at ϳ6 h. This meant that OTR induction by estrogen occurs through a traditional genomic mechanism, following a slower time course. In agreement with this, OTR expression was insensitive to the MAPK inhibition with the PD98059 compound (14) .
Over the past decade, numerous studies have documented direct effects of pituitary hormones on the skeleton, such as TSH, FSH, and ACTH, which have receptors in extraendocrine targets (1, 71, 90) . Moreover, several of these hormones, including TSHb, ACTH, and OT, are synthesized in nonpituitary tissues (14, 34, 86) . Physiologically, in the case of OT, a putative autocrine circuit may serve to coordinate the boneforming activity of neighboring osteoblasts. The local production of pituitary hormones in bone marrow and their action on bone cells together represent a novel dimension of the skeletal and endocrine physiology. This exquisite sensitivity of the skeleton to pituitary hormones seems to exceed that of their respective target endocrine organs. Therefore, it would not be surprising if the hitherto unrecognized local autocrine circuit of OT operates in tissues other than common endocrine target tissues, such as breast and ovary.
OT Is the Anabolic Mediator of Estrogen Action on Bone
Estrogen withdrawal in women due to menopause is often followed by rapid bone loss and a high-fracture risk (51) . Despite estrogen being the key hormonal regulator of bone metabolism in women and men, for a long time, it has been considerably difficult to establish the exact mechanisms by which estrogen exerts its protective effects on bone. It is known that loss of sex steroids stimulates the effects of aging on bone by decreasing protection against oxidative stress (2) and by T-cell activation, which, in turn, induces osteoclast formation by increasing the production of TNF-␣ and the number of OC precursors (26, 87) . Pacifici and colleagues (10) demonstrated that nude mice, which lack T lymphocytes, are protected from bone loss even though they undergo ovariectomy. However, another study found that ovariectomized nude rats (64) and nude RAG2-or TCR-␣-deficient mice, which lack functional T lymphocytes, were prone to cancellous bone loss to the same degree of wild-type mice (46) . Furthermore, it is well established that estrogen can attenuate hypogonadal hyperresorption through its effect on the osteoclast ER␣ to inhibit JNK phosphorylation (67) . In addition to direct effects on osteoclasts, estrogen also appears to indirectly regulate osteoclast formation and activity, suppressing RANKL production by osteoblastic, T and B cells (21) .
Given the essential role of the osteocyte in regulating bone remodeling, several studies have investigated whether osteocytes were targets of estrogen action. Hence, a study of Tomkinson et al. (82) showed that estrogen deficiency induced by GnRH treatment in premenopausal women increased osteocyte apoptosis in bone biopsy samples. Later, these findings were confirmed also in rats, in which ovariectomy resulted in osteocyte apoptosis in cancellous and cortical bone in the tibia (81) . In a more recent study, Emerton et al. (23) demonstrated that treatment of ovariectomized mice with a pan-caspase inhibitor prevented the increase in osteocyte apoptosis in cortical bones, but not in cancellous bone, and also prevented the increase in osteoclastic bone resorption on endocortical surfaces typically found in ovariectomized mice.
Accumulating evidence proved that osteocytes are an essential source of RANKL in the bone (88, 56) , but further studies are needed to establish whether osteocyte apoptosis might activate bone resorption, due to RANKL release from the apoptotic osteocytes or through effects of the apoptotic osteocytes on viable osteocytes. However, a preliminary report by Imai et al. (32) found that deletion of ER␣ from osteocytes using a Cre-recombinase driven by the dentin matrix acidic phosphoprotein 1 promoter leads to the decrease of osteoblast number on bone surfaces and bone formation rates but failed to have any effect on osteocyte apoptosis or on bone resorption. Obviously, overall effects seen in deletion of ER␣ in osteocytes need to be considered quite distinct from those seen following estrogen withdrawal, in particular, for the possible compensation by Er␤.
Despite that the main consequence of estrogen withdrawal is an increase in bone resorption, estrogen is also important for maintaining bone formation. Currently, the reduction of apoptosis (37), oxidative stress (2), and NF-B activity (11) are three key mechanisms explaining how estrogen leads to an increase in bone formation through direct effects on osteoblasts.
A recent study of Almeida et al. (3) reveals that ER␣ expressed in cells of the osteoblastic lineage is required for optimal accrual and maintenance of cortical bone mass. Moreover, authors show that these functions of ER␣ are due to its activity in osteoblast progenitors but not in mature osteoblasts or osteocytes. Specifically, deletion of ER␣ from pluripotent mesenchymal progenitors, using Prx1-cre, or from osteoblast progenitors, using Osx1-cre, produced similar reductions in cortical bone mass, whereas deletion from more mature cells, using Col1a1-cre, had no impact on bone mass or architecture (3). However, the potential role of ER␤ in modulating or compensating for loss of ER␣, remains unclear.
The revelation that OT has direct action on the skeleton (22, 76) and, at the same time, that local synthesis of OT by osteoblasts is estrogen-mediated (14) , provided further information on the mechanism by which estrogen may affect bone formation through the intermediary OT. Our recent work showed that the effect of 17␤-estradiol on bone mass in ovariectomized mice is also dependent on an intact-OTR axis (15) . To obviate confounding effects of elevated resorption and its inhibition by estrogen, instead of using estrogen-deprived rodents, we used wild-type mice with normal bone resorption and bone formation. As has been noted by others in nonovariectomized settings (73), we found that 17␤-estradiol does not affect osteoclast parameters, whether or not the mice are devoid of OTRs. In contrast, osteoblast numbers, bone formation, and cortical and trabecular bone mass are all enhanced significantly with 17␤-estradiol in wild-type mice. This anabolic action is attenuated in OTR Ϫ/Ϫ mice, suggesting that the effects of estrogen on bone mass are, at least in part, dependent on OTRs (15) .
To demonstrate that estradiol regulates bone cell activity through OT, OTR-silenced MC3T3 osteoblasts or primary cells obtained from OTR Ϫ/Ϫ mice were used (15) . After estrogen treatment in WT and OTR-expressing cells, osteoblast differentiation genes, such as osteopontin, BSP, osteocalcin, Runx2, Osterix, and ATF4 were upregulated (15) . Conversely, the lack of response appeared in OTR-silenced MC3T3 osteoblasts and in primary cells obtained from OTR Ϫ/Ϫ mice (15) . Histomorphometric studies showed that OTR Ϫ/Ϫ mice injected for a month with 17␤-estradiol did not show any change in bone formation parameters, compared with vehicle-injected OTR Ϫ/Ϫ mice, while the estrogen treatment significantly increased trabecular and cortical bone parameters in wild-type mice compared with their vehicle-injected littermates (15) , confirming the ability of estrogen to increase bone mass in an OTR-dependent manner. Further studies have investigated which cells-the osteoblasts, the osteoclasts, or both cellswere critical to inducing this anabolic action, since estrogen receptors are expressed by both osteoblasts and osteoclasts. This analysis has been particularly important as bone formation and bone resorption are closely coupled; thus, changes in resorption per se can affect bone formation and vice versa. Hence, as the anabolic action of estrogen on the skeleton is abolished in OTR Ϫ/Ϫ mice, it was crucial to study which OTR-bearing cell-osteoblast or osteoclast or both-mediates estrogen action.
The analysis was performed without the use of ovariectomized mice, because bone resorption rises immediately following ovariectomy, and this hyperresorption is targeted by the antiosteoclastic, rather than bone-forming action of estrogen. Conversely, the increase in bone mass in nonovariectomized mice is mainly induced from the stimulation of bone formation, rather than antiresorptive action. Using Coll2.3-Cre/Otr fl/fl mice, which do not express OTR in osteoblasts, and TRAPCre/Otr fl/fl mice, which do not express OTR in osteoclasts, it was established that the bone anabolic action of estradiol is mediated via osteoblastic OTR. Thus, only Coll2.3-Cre/Otr fl/fl mice failed to display increases in bone mass in response to 17␤-estradiol treatment (15) . These findings definitively established that the osteopenia of global OTR deficiency is mimicked by osteoblastic OTR deficiency.
These results are apparently in contrast to those obtained by Almeida et al. (3), discussed above, which showed that the deletion of ER␣ from pluripotent mesenchymal progenitors, using Prx1-cre, or from osteoblast progenitors, using Osx1-cre, produced reductions in cortical bone mass, whereas deletion from more mature cells, using Col1a1-cre, had no impact on bone mass or architecture.
Despite the fact that the deletions of OTR (8) and ER␣ (3) in osteoblasts have been both assessed by using Col1a1-cre (hence, at the same stage of osteoblast maturation), it is important to note that the regulation of OTR is mediated by both estrogen receptors, ER␣ and Er␤, with no differences in OTR expression during osteoblast lifespan (60, 74, 14, 15, 55) . Therefore, even though deletion of Er␣ had no impact on bone mass or architecture (3), the compensatory role of Er␤ needs to be considered. In fact, it cannot be excluded that in mouse models lacking Er␣ in mature osteoblasts, a compensatory mechanism activating OT/OTR system is exacerbated to maintain skeletal integrity. Probably, it could be argued that the indirect action of estrogen on bone tissue, mediated by OT, could be evolved to achieve skeletal surveillance, in particular, when one of the two estrogen receptors is deficient. Currently, the osteoblastic specific deletion of OTR, has been assessed only in mature osteoblast by using Col1a1-cre mice. To understand whether OT also regulates the earlier stage of osteoblast lifespan and how it could affect the skeleton, further studies, as assessed by deleting OTR from pluripotent mesenchymal progenitors or from osteoblast progenitors, are required.
The study reporting that some indirect estrogen effects on bone mass are dependent on OTRs has been assessed in mice (15) . However, human data, which have demonstrated a role of OT coupled to estrogen activity on bone metabolism, are also available (9, 22, 44) , confirming that it should not be considered a mouse-specific phenomenon. Indeed, lower OT levels have been found in postmenopausal women with osteoporosis compared with nonosteoporotic women (9) . Low OT levels have also been observed in athletes (43) and in girls with anorexia nervosa (44) . In these studies, Lawson et al. (43, 44) analyzed OT in two types of women characterized by their hypoestrogenic status: In amenorrheic athletes, a decrease in nocturnal OT secretion is strongly associated with alteration of bone architecture, assessed by high-resolution peripheral quantitative computed tomography; in women with anorexia nervosa, a decrease in nocturnal OT levels is associated with low bone mineral density. These results support the belief that OT may play a role in osteoporosis, when associated to altered levels of estrogen.
Perspectives and Significance
The contribution of OT in bone metabolism is a promising area of research that has recently made important progress. However, it is necessary that further studies in humans provide a more adequate understanding of OT's potential as a therapeutic agent in treating skeletal pathologies. OT physiology is indeed multifaceted per se. In addition, its dependence on other systems (e.g., sex steroids) has come to light recently (15) , so that studies on its integrative physiology will be necessary to fully understand the magnitude of OT effects on bone metabolism. Moreover, it should be taken into account that OT also participates in the regulation of energy balance. Several studies have associated the OT signal with energy balance regulation, showing that food intake in mice correspond to a peak of circulating OT levels across a 24-h period (91) , and hypothalamic OT mRNA expression is reduced with fasting and restored upon refeeding (42) . In addition, the reduced OT expression observed in single-minded 1 (Sim1) haploinsufficient mice explains their hyperphagic obesity (42) , which can be rescued with OT treatment (80) . Also, in humans, the mutation of SIM1 was associated with obesity (31) , and in patients with Prader-Willi syndrome, who suffer from hyperphagia and obesity, the number and size of OT neurons in the paraventricular nucleus of the hypothalamus were reduced (72) . OT can also influence body mass independently from suppression of food intake. Thus, mice lacking OT receptors develop late-onset obesity with increased abdominal fat pads without changes to daily intake of chow (75) . Of note, conditional knockout mice in which forebrain OTRs were deleted postnatally showed reduction in body mass (45) , suggesting that OT's effects on energy metabolism are mediated within the central nervous system. On the other hand, studies on OT regulation of gastric motility support both central and peripheral OT action (61, 89) . Likewise, several reports showed that circulating OT regulates adiposity since adipocytes express its receptors (83). Elabd et al. (22), identified OTR as a potential regulator of the osteoblast/adipocyte balance in human multi-potent adipose-derived stem (hMADS) cells. Both OT and carbetocin (a stable OT analog) negatively modulated adipogenesis while promoting osteogenesis in both hMADS cells and human bone marrow mesenchymal stromal cells (22) . Ovariectomized mice and rats were found to have significantly decreased OT levels compared with sham-operated controls, and subcutaneous OT injection reduced marrow adiposity and reversed bone loss (22) . The tight association between bone loss and increased bone marrow adiposity should be taken into account. In view of accumulating evidence that demonstrated a key role of OT in regulating osteogenesis and adipogenesis, controlling the balance between the two pathways will open new avenues for important therapeutic strategies (58) .
It is well known that an inverse relationship exists between osteoblasts and adipocytes, which are derived from the same precursor in bone marrow. However, the fate to commit to either lineage is not well characterized and despite the evident correlation of marrow adipose tissue accumulation with osteoporosis and osteopenia (27) , it is unclear whether excessive marrow adipose tissue could directly influence bone metabolism or whether the bone loss occurring could provoke changes in the marrow microenvironment that indirectly influences marrow adipose tissue formation. Despite the similarities in terms of development of marrow and white adipocytes, there are controversial studies showing either positive or negative correlations between these two distinct forms of adipose tissue. Di Iorgi et al. (19) demonstrated that adolescents and young adults with high marrow adiposity in the appendicular skeleton did not display altered subcutaneous or visceral fat depots. Conversely, other authors found a positive correlation between marrow adiposity and visceral fat mass in some settings, suggesting that the correlation of these two types of adipose tissue could be compartment-specific (8) .
Several studies have documented that an osteoporotic phenotype, beside reduction in bone formation and increase in bone resorption, displays a larger fatty marrow cavity (27, 78) , suggesting a correlation between reduced estrogen levels and increased marrow adiposity.
Moreover, it has been also shown that the increase in adipogenesis often associated with postmenopausal period might be caused by high circulating levels of Wnt inhibitors such as Dkk1 and SFRP2 (12) , but their contribution in fat mass augmentation is not completely understood. Most likely, these circulating Wnt inhibitors, as well as sclerostin, can force mesenchymal cells to differentiate into other cell types, such as adipocytes rather than osteoblasts (41) .
Sclerostin inhibits Wnt signaling by binding to the coreceptors LDL receptor-related proteins (LRPs) 5 and 6, preventing formation of the active LRP/Frizzled complex (40) . Targeting deletion of sclerostin in mice leads to high bone mass, due to a great increase in bone formation in both trabecular and cortical bone (47) . An antibody-based sclerostin inhibition increased bone mass and strength in healthy female rats and rescued ovariectomy-induced bone loss (48) . The identification of the Wnt/␤-catenin signaling pathway as a major regulator of bone mass (5) has led to considerable interest on potential cross talk between this pathway and estrogen signaling (4) . Studies in humans have found that serum sclerostin levels are negatively correlated with the free estradiol index in postmenopausal women (53) and that estrogen treatment of postmenopausal women reduces circulating sclerostin levels (54). However, thus far, few data have correlated sclerostin levels with body mass. Only one cross-sectional study, performed by Urano et al. (84) identified the relationship between serum sclerostin levels and markers of metabolic disease. These authors measured serum sclerostin levels in 352 Japanese postmenopausal women and analyzed the relationship of these levels with abdominal fat mass. Their result shows that serum sclerostin levels were positively correlated with percentages of abdominal and gynoid fat (84) . Further studies addressing this issue are clearly needed, but this raises an intriguing, albeit speculative, question of whether high sclerostin levels expressed by bone marrow cells from OTR-deficient mice (unpublished data) could indicate that expression of the Wnt inhibitor is regulated by OT. This hypothesis could also explain the existing link between low levels of estrogen and high levels of sclerostin. Since it was demonstrated that OT is one of the mediators of the anabolic action of estrogen on bone tissue, mainly through the regulation of ATF4 and BMP2 (76) , the finding that such action also concerns the Wnt pathway, would expand the importance of OT as a regulator of bone metabolism (Fig. 1) .
In addition to studies that found a correlation between serum levels of estrogen and sclerostin (53, 54), Galea et al. (25) investigated their association at the molecular level. They established, by using subtype-selective receptor agonists and antagonists against the ERs, the contributions of ER␣ and ER␤ to the regulation of sclerostin gene, Sost. The authors showed the involvement of ERK signaling through a nongenomic action of estrogen receptor in Sost downregulation (25) . The finding that MAPK/ERK blockade prevents ER␤-mediated Sost downregulation (25) is consistent with the report showing that estrogen stimulates OT production, via a nongenomic, ERE-independent pathway involving Erk phosphorylation (14) . Thus, the nongenomic activation of ERK signaling by estrogen enhances OT synthesis, which occurs rapidly within 2 h (14). Consequently, it could be hypothesized that locally secreted OT by estrogen stimulation might, in turn, regulate Sost expression. Fig. 1 . Osteoblasts and adipocytes are derived from a common mesenchymal stem cell precursor, and their balance is regulated by molecules that lead to osteoblastogenesis and inhibit adipogenesis or vice versa. Activation of Wnt signaling pathway inhibits adipogenesis, while supporting osteogenesis. In contrast, PPAR␥ promotes the differentiation of mesenchymal stem cells into adipocytes over osteoblasts. Besides these proteins, the Wnt inhibitor molecules are also necessary to control the balance between osteogenesis and adipogenesis. The interplay of these molecular regulators could be crucial in the pathogenesis of obesity, as it was found to be essential in osteoporosis. Future studies could reveal a putative role of oxytocin in controlling the balance in favor of osteogenesis at the expense of adipogenesis through downregulation of sclerostin synthesis.
Currently, there are no data demonstrating the involvement of OT in Wnt signal, either in bone tissue or in other tissues. Therefore, further analysis based on this hypothesis could expand investigations on OT contribution to bone metabolism and, in addition, may also open new research on the balance between osteogenesis and adipogenesis governed by OT, in the event it is mediated by the Wnt pathway through its inhibitor sclerostin.
In view of a potential role of OT to shift the balance in favor of osteogenesis at the expense of adipogenesis, further studies could be extremely relevant in understanding the role of OT/Oxtr/estrogen system in the regulation of adipose tissue physiology. Thus, recombinant OT and its analogs would be extremely useful as skeletal anabolic agents to treat osteoporosis but might also have potential utility in adipose tissuerelated pathologies.
Although the step of relating the data to human patients is more problematic and, in addition, the therapeutic potential of OT to treat skeletal and metabolic conditions in humans remains to be determined, data from osteoporotic and genetically obese rodent models, as well as application of oxytocin in humans in other areas of research, have hitherto revealed encouraging results.
Albeit the major issue arising from using OT treatment would be that its receptor, as well as other G protein-coupled receptors, could undergo rapid desensitization after persistent stimulation (24) , thus developing tolerance, several reports have shown its efficacy when administered chronically (18, 50) . Therefore, further investigations will be relevant to determine whether oxytocin is also effective when administered long term and whether results obtained in rodents can be translated to human subjects. Specifically, to perform therapeutic application in humans, it will be required to consider that oxytocin has effects on central nervous system (e.g., analgesia) (30) and heart (e.g., stimulates the contractility of the cardiac muscle and increases blood pressure) (59, 16) . Nevertheless, encouraging results have been obtained by using intranasal oxytocin therapy in humans, in which OT has proved to be effective in increasing trusting behavior (36) , positive communication (20) , in-group favoritism (17) , and reducing social stress reactivity (29) .
Conclusions
In bone tissue, the repletion of OT signaling might clinically serve as nonsteroid source to restore bone formation for those forms of osteoporosis due to osteoblast defects. In addition, OT is responsible for the initial mobilization and subsequent restoration of the maternal skeleton during periods of calcium stress in pregnancy and lactation. Therefore, OT analogs could be employed as anabolic stimuli to restore the skeletal loss occurring after pregnancy and lactation.
At the same time, accumulating evidence has confirmed the ability of OT to regulate energy balance. Considering the tight relationship between skeletal metabolism and energy homeostasis, the potential role of OT in this network needs to be clarified, as well the relative contribution of centrally and peripherally mediated effects.
